Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia.

about

Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records

P2860

Q33571590-69AB0329-8DF1-4D9B-843E-064DD1AB441C

P2860

Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia.

Item

http://www.wikidata.org/entity/Q45871229

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Utilization of recombinant act ...... with and without haemophilia.

@en

Utilization of recombinant act ...... with and without haemophilia.

@nl

type

Item

label

Utilization of recombinant act ...... with and without haemophilia.

@en

Utilization of recombinant act ...... with and without haemophilia.

@nl

prefLabel

Utilization of recombinant act ...... with and without haemophilia.

@en

Utilization of recombinant act ...... with and without haemophilia.

@nl

P1476

Utilization of recombinant act ...... s with and without haemophilia

@en

P2093

D M Arnold

http://www.w3.org/2001/XMLSchema#string

I R Walker

http://www.w3.org/2001/XMLSchema#string

J Carruthers

http://www.w3.org/2001/XMLSchema#string

J Reed

http://www.w3.org/2001/XMLSchema#string

K Decker

http://www.w3.org/2001/XMLSchema#string

K E Webert

http://www.w3.org/2001/XMLSchema#string

L Molnar

http://www.w3.org/2001/XMLSchema#string

M Pai

http://www.w3.org/2001/XMLSchema#string

T Almonte

http://www.w3.org/2001/XMLSchema#string

W Seroski

http://www.w3.org/2001/XMLSchema#string

P2860

Transfusion medicine service policies for recombinant factor VIIa administration.

"Off-license" use of recombinant activated factor VII.

Recombinant activated factor VII for acute intracerebral hemorrhage.

Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review.

Use of recombinant activated factor VII to treat the acquired coagulopathy of trauma.

Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal.

Thromboembolic adverse events after use of recombinant human coagulation factor VIIa.

Challenges in the therapeutic use of a "so-called" universal hemostatic agent: recombinant factor VIIa.

Developing a tracking system for coagulation factor concentrates in southern Ontario.

Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate.

P304

518-526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2516.2007.01490.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Anthony K. C. Chan

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5963531

http://www.w3.org/2001/XMLSchema#string

P698

17880438

http://www.w3.org/2001/XMLSchema#string

P921

hemophilia

Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia.

about

P2860

P2860

Utilization of recombinant activated factor VII in southern Ontario in 85 patients with and without haemophilia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921